Risk Factors for poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis in south korea

Multi-drug resistant tuberculosis (MDR-TB) is a major health problem that threatens the success of tuberculosis (TB) control programs worldwide [1, 2]. The World Health Organization (WHO) launched the global surveillance project for anti-TB drug resistance in 1994 [1]. An estimated 3.3% (2.2-4.4%) of new cases and 20% (14-27%) of repeat TB cases were caused by MDR-TB in 2014, consistent with recent years [1]. In 2014, an estimated 480,000 people worldwide developed MDR-TB, and 190,000 people died as a result [1]. MDR-TB is caused by strains of Mycobacterium tuberculosis that are resistant to both isoniazid (INH) and rifampicin (RFP), the two most potent TB drugs. In 1965, the incidence of TB in South Korea was 668 cases per 100,000 [3]. Since the implementation of standardized therapeutic approaches in the 1980s, the prevalence of TB and Hanyang Med Rev 2016;36:262-268 https://doi.org/10.7599/hmr.2016.36.4.262 pISSN 1738-429X eISSN 2234-4446 Jun Ho Yang, M.D, Hyun Oh Park, M.D, Joung Hun Byun, M.D, Sung Hwan Kim, M.D, Sung Ho Moon, M.D, Jong Duk Kim, M.D and Dea Yeon Kim, M.D